Technology
back to specific software requirements. This documentation and process is at the heart of demonstrating safe and compliant software development. A structured approach can help identify potential malfunctions. At the same time, the business should have
a clear plan for how bugs, vulnerabilities and quality issues will be managed after launch and throughout the entire product lifecycle. Post Market Surveillance (PMS) will be necessary once the product is out on the market and manufacturers are responsible for monitoring its components and ensuring they continue to meet safety and performance standards. Another key element to developing safe and compliant SaMDs is testing and validation. For example, a workflow that includes image preprocessing followed by a basic landmark- recognition step will require validation of each operation to further ensure that all outputs are directly tied to a defined requirement to transform it into medical-grade software. Techniques like quantisation can be useful for developing lightweight yet high-performance models as it reduces the precision of model weights and activations to make inference faster and more efficient, however, when these algorithms are intended for a regulated environment, each stage needs greater accuracy and traceability.
Regulatory market conditions: UK, US, EU Form a business perspective, the success of a product often depends on gaining competitive advantage and getting to market as rapidly as possible. Avoiding highly complex environments where a device may encounter a bottleneck or even have to retreat from the market is key. Geographical considerations are therefore key to selecting a launch market for an AI-driven device or SaMD. Currently the US offers an environment of
greater predictability over timelines and costs compared to other markets such as the UK and EU. There is also FDA guidance on the positioning of products as general wellness devices and clinical decision support software which are not regulated as medical devices. Although manufacturers should be aware that enforcement discretion can be overturned by the FDA, the go to market process is quite streamlined. At the other end of the spectrum for the time being, the EU presents a potential risk of bottlenecks caused by overburdened Notified Bodies (NB). In addition to timing concerns, NB fee structures and defined timelines for certifications are not standardized, making it hard to plan a market launch
for the EU. To overcome this limitation, the European Commission published a draft on 12th December 2025 implementing regulation outlining the need to set specific quotation and timeline requirements that NBs must meet to ensure greater regulatory consistency
and predictability. The EU also published COM (2025) 1023: a proposal to amend the MDR, the IVDR and related legislation to simplify rules on medical devices and IVDs to alleviate some of the pressures on NBs and manufacturers. Among the proposals is amendment to the
created equal. Not all wipes are
Meets ALL mandatory sporicidal testing requirements
True sporicidal efficacy: Validated to EN 14885:2022
Find out
more
June 2026 I
www.clinicalservicesjournal.com 55
LALAKA -
stock.adobe.com
Copyright © Tristel Solutions Limited -Mkt-Adv-3590 - 30/APR/2026 - V1
t
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72
